(CercleFinance.com) – TME Pharma reported new positive data on Friday in aggressive brain cancer in adults, which allowed its stock to rebound on Friday on the Paris Stock Exchange.
The biotech announced this morning that another newly diagnosed glioblastoma patient receiving NOX-A12, its lead drug candidate, had reached 18 months of survival, bringing overall 18-month survival to 67%.
The 18-month survival rate for patients treated with NOX-A12, in addition to bevacizumab (Avastin) and radiotherapy, is now 13 times higher than the 18-month survival rate of 5% observed in the cohort of reference, underlines the company.
At the same time, median overall survival continues to improve and has already exceeded 18 months, while the reference cohort achieved a median overall survival of 10.5 months.
Aram Mangasarian, CEO of TME Pharma, believes his company has accumulated ‘irrefutable’ clinical evidence to a level where NOX-A12-based therapies now have the potential to be considered the best treatment available for patients with glioblastoma.
TME Pharma plans to obtain a registration dossier from the FDA as well as access to an accelerated pathway by the end of the first quarter of 2024.
Following these announcements, TME Pharma shares jumped 18% on Friday on the Paris Stock Exchange.